Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis

Completed · Phase 4 · Has a placebo group

Conditions studied: Pleural Effusion

In brief

Prospective Randomized Double-Blind Controlled Trial of Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis versus Standard of care Talc therapy in patients with recurrent pleural effusion.

Key facts

Study ID

NCT04806373

Run by

Memorial Healthcare System

People needed

27

Starts

2021-06-15

Expected to finish

2023-12-14

Last updated by the study team

2025-06-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > 18 years
• Symptomatic pleural effusion requiring intervention
• Expected survival > 3 months
• Written informed consent to trial participation

You may not qualify if…

• Females who are pregnant or lactating
• Inability to obtain consent from the patient or patient's designated representative.
• Inability of the patient to comply with the protocol.
• Previously documented adverse reaction to talc or cathflo activase.
• Oral or intravenous steroid therapy

Where it is running

• Memorial Healthcare System — Hollywood, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.